Ublituximab

ApprovedRecruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Multiple Sclerosis

Conditions

Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting

Trial Timeline

Nov 28, 2025 → Aug 1, 2029

NCT ID

NCT07225361

About Ublituximab

Ublituximab is a approved stage product being developed by TG Therapeutics for Multiple Sclerosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07225361. Target conditions include Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting.

What happened to similar drugs?

20 of 20 similar drugs in Multiple Sclerosis were approved

Approved (20) Terminated (0) Active (0)

✅Mirabegron + PlaceboAstellas PharmaApproved

✅Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + PlaceboAstellas PharmaApproved

✅TeclistamabJohnson & JohnsonApproved

✅BortezomibJohnson & JohnsonApproved

✅DaratumumabJohnson & JohnsonApproved

✅Mavenclad®MerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06864936	Pre-clinical	Recruiting	Jan 1, 2026	Jun 30, 2027	Multiple Sclerosis (MS) - Relapsing-remitting
NCT07225361	Approved	Recruiting	Nov 28, 2025	Aug 1, 2029	Multiple Sclerosis
NCT04130997	Phase 3	Active	Nov 18, 2019	May 31, 2032	Relapsing Multiple Sclerosis (RMS)
NCT03381170	Phase 2	Completed	Jun 1, 2017	Nov 11, 2022	Relapsing Remitting Multiple Sclerosis
NCT01647971	Phase 1/2	Completed	Jul 19, 2012	May 1, 2015	Non-Hodgkins Lymphoma

Competing Products

20 competing products in Multiple Sclerosis

See all competitors

Product	Company	Stage	Hype Score
mRNA-1195	Moderna	Phase 2	0
NEX-20A	Nanexa AB	Phase 1	23
mRNA-2736	Moderna	Phase 1	0
mRNA-2808	Moderna	Phase 2	0
Placebo + Pirtobrutinib	Eli Lilly	Phase 2	27
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide	Eli Lilly	Phase 1/2	32
agenT-797	MiNK Therapeutics	Phase 1	19
Duloxetine Hydrochloride (HCI) + Placebo	Eli Lilly	Phase 3	40
Temferon	Genenta Science	Phase 1/2	14
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)	Celltrion	Phase 3	47
CT-P53 + US-Ocrevus + EU-Ocrevus	Celltrion	Phase 3	47
CS-0777 tablets + CS-0777 tablets + CS-0777 tablets	Daiichi Sankyo	Phase 1	29
ASP7487, Velcade, Dexamethasone	Astellas Pharma	Phase 1/2	24
PHE885	Novartis	Phase 2	27
Mirabegron + Placebo	Astellas Pharma	Approved	43
Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo	Astellas Pharma	Approved	43
Denileukin Diftitox (Ontak)	Eisai	Phase 1	21
Palonosetron	Eisai	Phase 2	35
BIW-8962	Kyowa Kirin	Phase 1	21
KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor)	Kyowa Kirin	Phase 2	35